proxyvotesnow.com

Home › Companies › VIRIDIAN THERAPEUTICS INC. › 2023-2024

VIRIDIAN THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and VIRIDIAN THERAPEUTICS INC.’s Form 8-K, filed 2024-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 162Asset managers
  • 1,008Fund votes
  • 2024-06-17Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore VIRIDIAN THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by VIRIDIAN THERAPEUTICS INC.

These tallies are VIRIDIAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VIRIDIAN THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-17
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Stephen Mahoney 56,413,440---- 156,1061,902,188 Majority: yes
Elect Director: Arlene M. Morris 31,631,097---- 24,938,4491,902,188 Majority: yes
Proposal 2: Ratification of the selection of KPMG LLP as the Company's independent auditor for 2024: 58,418,56931,74821,417 ---- Majority: yes
Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers: 32,797,46823,748,21623,862 --1,902,188 Majority: yes
Proposal 4: Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares available for issuance thereunder: 32,220,47424,328,88820,184 --1,902,188 Majority: yes

Source: VIRIDIAN THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-20 — read the filing on EDGAR.

How asset managers voted at the VIRIDIAN THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 162 asset managers that disclosed a VIRIDIAN THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

58% Majority: yes · of votes cast

FOR 58%AGAINST 42%
FOR: 32,797,468AGAINST: 23,748,216

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers:”): 32,797,468 for, 23,748,216 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,798,536 outstanding shares: 51.4% for, 37% against (89% of the company cast a for/against vote).

The 162 asset managers below cast 50.9% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 50.9%AGAINST 49.0%
FOR: 50.9%AGAINST: 49.0%ABSTAIN: 0.0%
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,072,27017,953,987 00Against
State Street6,778,72628,198 00For
Paradigm Biocapital Advisors LP04,778,003 00Against
Vanguard3,179,3820 00For
VR Adviser, LLC3,082,6700 00For
Deep Track Capital, LP3,039,3600 00For
AllianceBernstein02,530,329 00Against
BlackRock9,1272,352,024 00Against
COMMODORE CAPITAL LP1,934,6530 00For
Fairmount Funds Management LLC1,845,8130 00For
Novo Holdings A/S1,750,0000 00For
Vivo Capital, LLC1,678,2070 00For
Nuveen1,300,6110 00For
GREAT POINT PARTNERS LLC1,286,1600 00For
PERCEPTIVE ADVISORS LLC1,255,9660 00For
TIAA1,251,6110 00For
GEODE CAPITAL MANAGEMENT, LLC1,158,9150 00For
PICTET ASSET MANAGEMENT SA0987,650 00Against
Charles Schwab0883,758 00Against
Polar Capital Holdings Plc0882,660 00Against
5AM Venture Management, LLC736,5950 00For
Citadel727,0300 00For
Yiheng Capital Management, L.P.668,2360 00For
MPM BioImpact LLC622,0290 00For
Octagon Capital Advisors LP620,0000 00For

Showing the 25 largest of 162 asset managers. See all 162 in the interactive database.

2. To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including to increase the number of shares available for issuance thereunder.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

57% Majority: yes · of votes cast

FOR 57%AGAINST 43%
FOR: 32,220,474AGAINST: 24,328,888

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Approval of a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares available for issuance thereunder:”): 32,220,474 for, 24,328,888 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,798,536 outstanding shares: 50.5% for, 38% against (89% of the company cast a for/against vote).

The 51 asset managers below cast 37% of the shares they voted on this item FOR (7,880,117 for, 13,455,887 against).

FOR 37%AGAINST 63%
FOR: 7,880,117 (36.9%)AGAINST: 13,455,887 (63.0%)ABSTAIN: 25,978 (0.1%)
Largest asset managers voting on “To approve a further amendment and restatement of the Company's Amended and Restated 2016 Equity Incentive Pla” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,093,2068,555,686 00Against
Vanguard3,062,0310 00For
State Street3,1162,941,945 00Against
TIAA1,251,6110 00For
AllianceBernstein01,014,023 00Against
BlackRock939,5180 00For
Yiheng Capital Management, L.P.668,2360 00For
Charles Schwab427,0420 00For
Principal164223,805 00Against
Direxion Shares ETF Trust0191,602 00Against
Russell Investments131,7540 00For
Equitable77,57338,700 00For
CARILLON SERIES TRUST0115,998 00Against
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares069,048 00Against
Nushares ETF Trust46,6650 00For
Dimensional038,954 00Against
Lincoln Financial035,700 00Against
Advisors' Inner Circle Fund III035,035 00Against
AIG/SunAmerica024,515 00Against
Brighthouse08,831 13,7870Abstain
Northern Trust022,008 00Against
Global X20,7920 00For
John Hancock018,538 00Against
Nationwide39617,561 00Against

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

3. To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 58,418,569AGAINST: 31,748

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the selection of KPMG LLP as the Company's independent auditor for 2024:”): 58,418,569 for, 31,748 against, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,798,536 outstanding shares: 92% for, 0.1% against (92% of the company cast a for/against vote).

The 49 asset managers below cast 99.9% of the shares they voted on this item FOR (20,667,298 for, 470 against).

FOR 99.9%
FOR: 20,667,298 (99.9%)AGAINST: 470 (0.0%)ABSTAIN: 13,787 (0.1%)
Largest asset managers voting on “To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the yea” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity9,648,8920 00For
Vanguard3,062,0310 00For
State Street2,944,591470 00For
TIAA1,251,6110 00For
AllianceBernstein1,014,0230 00For
BlackRock939,5180 00For
Charles Schwab427,0420 00For
Principal223,9690 00For
Direxion Shares ETF Trust191,6020 00For
Russell Investments131,7540 00For
Equitable116,2730 00For
CARILLON SERIES TRUST115,9980 00For
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares69,0480 00For
Nushares ETF Trust46,6650 00For
Dimensional38,9540 00For
Lincoln Financial35,7000 00For
Advisors' Inner Circle Fund III35,0350 00For
AIG/SunAmerica24,5150 00For
Brighthouse8,8310 13,7870Abstain
Northern Trust22,0080 00For
Global X20,7920 00For
John Hancock18,5380 00For
Nationwide17,9570 00For
Pacific Life17,5500 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Arlene M. Morris

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

56% Majority: yes · of votes cast

FOR 56%WITHHELD 44%
FOR: 31,631,097WITHHELD: 24,938,449

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Arlene M. Morris”): 31,631,097 for, 24,938,449 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,798,536 outstanding shares: 49.6% for, 39% withheld (89% of the company cast a for/withheld vote).

The 48 asset managers below cast 100% of the shares they voted on this item FOR (6,636,994 for, 0 against).

FOR 32%ABSTAIN 68%
FOR: 6,636,994 (32.1%)ABSTAIN: 14,033,061 (67.9%)
Largest asset managers voting on “To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,093,2060 8,555,6860Abstain
Vanguard3,062,0310 00For
State Street3,1160 2,941,9450Abstain
TIAA1,251,6110 00For
AllianceBernstein00 1,014,0230Abstain
BlackRock939,5180 00For
Charles Schwab00 427,0420Abstain
Principal00 223,9690Abstain
Direxion Shares ETF Trust00 191,6020Abstain
Russell Investments00 131,7540Abstain
Equitable77,5730 38,7000For
CARILLON SERIES TRUST00 115,9980Abstain
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares00 69,0480Abstain
Nushares ETF Trust46,6650 00For
Dimensional00 38,9540Abstain
Lincoln Financial00 35,7000Abstain
Advisors' Inner Circle Fund III00 35,0350Abstain
AIG/SunAmerica00 24,5150Abstain
Brighthouse00 22,6180Abstain
Northern Trust22,0080 00For
Global X00 20,7920Abstain
John Hancock00 18,5380Abstain
Nationwide00 17,9570Abstain
Pacific Life17,5500 00For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

5. To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until their successors are duly elected and qualified: Stephen Mahoney

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 56,413,440WITHHELD: 156,106

VIRIDIAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen Mahoney”): 56,413,440 for, 156,106 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,798,536 outstanding shares: 88% for, 0.3% withheld (89% of the company cast a for/withheld vote).

The 48 asset managers below cast 100% of the shares they voted on this item FOR (20,656,268 for, 0 against).

FOR 99.9%
FOR: 20,656,268 (99.9%)ABSTAIN: 13,787 (0.1%)
Largest asset managers voting on “To elect the two Class III director nominees to serve until the 2027 Annual Meeting of Stockholders, and until” at VIRIDIAN THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity9,648,8920 00For
Vanguard3,062,0310 00For
State Street2,945,0610 00For
TIAA1,251,6110 00For
AllianceBernstein1,014,0230 00For
BlackRock939,5180 00For
Charles Schwab427,0420 00For
Principal223,9690 00For
Direxion Shares ETF Trust191,6020 00For
Russell Investments131,7540 00For
Equitable116,2730 00For
CARILLON SERIES TRUST115,9980 00For
QUANTITATIVE MASTER SERIES LLC92,7190 00For
ProShares69,0480 00For
Nushares ETF Trust46,6650 00For
Dimensional38,9540 00For
Lincoln Financial35,7000 00For
Advisors' Inner Circle Fund III35,0350 00For
AIG/SunAmerica24,5150 00For
Brighthouse8,8310 13,7870Abstain
Northern Trust22,0080 00For
Global X20,7920 00For
John Hancock18,5380 00For
Nationwide17,9570 00For
Pacific Life17,5500 00For

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Largest VIRIDIAN THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of VIRIDIAN THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 63,798,536 shares outstanding at the time of that meeting.

Top VIRIDIAN THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 29.82%
2State Street 10.67%
3Paradigm Biocapital Advisors LP 7.49%
4Vanguard 4.98%
5VR Adviser, LLC 4.83%
6Deep Track Capital, LP 4.76%
7AllianceBernstein 3.97%
8BlackRock 3.70%
9COMMODORE CAPITAL LP 3.03%
10Fairmount Funds Management LLC 2.89%

Reported VIRIDIAN THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VIRIDIAN THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Entities affiliated with Fairmount Funds Management LLC 21.88% DEF14A
FMR (Fidelity) 19.20% 13F
Entities affiliated with FMR LLC 11.95% DEF14A
Entities affiliated with Venrock Healthcare Capital Partners 8.71% DEF14A
BlackRock 8.51% 13F
Entities affiliated with Deep Track Capital, LP 8.43% DEF14A
Entities affiliated with Paradigm BioCapital Advisors LP 8.31% DEF14A
State Street 7.04% 13F
Vanguard Group 6.79% 13F
Entities affiliated with Perceptive Advisors LLC 6.30% DEF14A

Percentages above are of 63,798,536 shares outstanding, as reported by VIRIDIAN THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIRIDIAN THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VIRIDIAN THERAPEUTICS INC.'s shareholder meeting held 2024-06-17, in the 2023-2024 proxy season, 162 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,008 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 58% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VIRIDIAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-20.

VIRIDIAN THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.